Carbenoxolone

Subscribe to Selected New Research on Carbenoxolone

274 relevant articles (20 outcomes, 43 trials/studies) found for this Bio-Agent

Description: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.

Also Known As:

18alpha-Carbenoxolone; 18alpha-Glycyrrhetinic Acid 3beta-O-Hemisuccinate; Biogastrone; Bioral; Byk Brand of Carbenoxolone Disodium Salt; Carbeneoxolone; Carbenoxolone Disodium Salt; Carbenoxolone Sodium; Carbosan; Duogastrone; Glycyrrhetinic Acid 3-O-hemisuccinate; Pharmaxolon; Rowa Brand of Carbenoxolone Disodium Salt; Sanodin; 18alpha Carbenoxolone; 18alpha Glycyrrhetinic Acid 3beta O Hemisuccinate; 3-O-hemisuccinate, Glycyrrhetinic Acid; 3beta-O-Hemisuccinate, 18alpha-Glycyrrhetinic Acid; Acid 3-O-hemisuccinate, Glycyrrhetinic; Acid 3beta-O-Hemisuccinate, 18alpha-Glycyrrhetinic; Glycyrrhetinic Acid 3 O hemisuccinate; Carbenoxalone; Olean-12-en-29-oic acid, 3-(3-carboxy-1-oxopropoxy)-11-oxo-, (3beta,20beta)-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Terpenes: 149

Triterpenes: 64

Pentacyclic Triterpenes: 12

Glycyrrhetinic Acid: 93

Experts

1.	Belluardo, Natale: 3 articles (09/2005 - 01/2004)
2.	Condorelli, Daniele: 3 articles (09/2005 - 01/2004)
3.	Gareri, Pietro: 3 articles (09/2005 - 01/2004)
4.	De Sarro, Giovambattista: 3 articles (09/2005 - 01/2004)
5.	Russo, Emilio: 2 articles (09/2005 - 12/2004)
6.	Barresi, Vincenza: 2 articles (09/2005 - 12/2004)
7.	Trovato-Salinato, Angela: 2 articles (09/2005 - 12/2004)
8.	Flatt, Peter R: 1 article (04/2008)
9.	McKillop, Aine M: 1 article (04/2008)
10.	Gault, Victor A: 1 article (04/2008)

Related Diseases

1.	Duodenal Ulcer (Curling's Ulcer) 01/01/1978 - "The result is highly significant (P less than 0.016) and confirms the therapeutic efficacy of carbenoxolone sodium positioned-release capsules in the treatment of duodenal ulcers" 01/01/1976 - "Carbenoxolone sodium has been shown to accelerate the rate of healing of both gastric and duodenal ulcers, but its overall value in duodenal ulcer is probably less because of the high rate of natural remission of duodenal ulcers" 01/13/1979 - "These results confirm the therapeutic efficacy of carbenoxolone sodium in duodenal ulcer" 01/01/1981 - "A double-blind randomized trial was performed in order to evaluate the efficacy of carbenoxolone (Biogastron duodenal) in reducing recurrences of duodenal ulcer" 01/13/1979 - "In a double-masked trial, 43 patients with an endoscopically confirmed, symptomatic duodenal ulcer were allocated at random to treatment with either carbenoxolone sodium or placebo, both provided in identical "positioned-release" capsules" Order ALL the reference details at left...
2.	Ulcer 01/01/1977 - "Complete ulcer healing occurred in a significantly greater number of patients receiving Duogastrone than placebo, the significance being greater after four and eight weeks treatment (P less than 0-01) than at 12 weeks (P less than 0-02)" 04/01/1978 - "Carbenoxolone may exert its metabolic effects systemically, but its ulcer-healing effects topically; additional studies are needed to test this hypothesis." 02/01/2001 - "The anticonvulsant potential of gap-junction blockers such as carbenoxolone, now in clinical use for treatment of ulcer disease, should be considered." 01/01/1998 - "In particular, 38b and 39b showed a potent anti-ulcer activity, 3- to 25-fold higher than carbenoxolone" 06/01/1990 - "Its anti-ulcer activities were similar to those of carbenoxolone" Order ALL the reference details at left...
3.	Seizures (Seizure) 12/01/2004 - "In particular, intravenous or intraperitoneal administration of carbenoxolone (5-30 mg/kg) produced a dose-dependent and significant reduction in the clonic and tonic phases of the audiogenic seizures in GEPRs" 01/19/2004 - "Systemic administration of carbenoxolone (1-40 mg/kg, intraperitoneally (i.p.)) was able to produce a dose-dependent decrease in DBA/2 audiogenic seizure severity score" 04/29/2003 - "CONCLUSION: It can be concluded that carbenoxolone possesses anticonvulsant, muscle relaxant and hypnotic effects, which could contribute to the control of petit mal and grand mal seizures." 04/29/2003 - "In this model, carbenoxolone in doses of 200 and 300 mg/kg prolonged the onset time of seizure and decreased the duration of seizures" 04/29/2003 - "Thus, we considered the possible anticonvulsant effects of carbenoxolone in animal seizure models" Order ALL the reference details at left...
4.	Stomach Ulcer (Gastric Ulcer) 04/01/1967 - "Side effects of carbenoxolone sodium: a study of ambulant therapy of gastric ulcer." 01/01/1987 - "Thirty-four patients with gastric ulcer were treated with the new Bulgarian preparation pharmaxolon-Pharmachim, for 20 days under clinical conditions" 01/01/1981 - "Carbenoxolone effectively reduced the gastric ulcer formation by cold-restraint stress when it was administered i.p" 01/01/1980 - "Between 1970 and 1979, 140 patients aged between 19 and 84 years with endoscopically confirmed gastric ulcer (GU), were treated with Biogastrone in reducing doses for 6 months" 01/01/1980 - "Long-term therapy with carbenoxolone in the prevention of recurrence of gastric ulcer" Order ALL the reference details at left...
5.	Peptic Ulcer (Peptic Ulcers) 01/01/1976 - "Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease." 01/01/1998 - "When I was a medical student, not surprisingly, the standard therapy for a peptic ulcer was an antacid possibly combined with carbenoxolone" 01/01/1988 - "With the important side effects of carbenoxolone in mind, it is no wonder that medical treatment was no alternative to surgery in patients suffering from recurrent peptic ulcer.(ABSTRACT TRUNCATED AT 250 WORDS)" 02/17/1984 - "This hypothesis is supported by the finding that carbenoxolone, a drug accelerating peptic ulcer healing by a mechanism which does not involve inhibition of acid secretion, stimulates gastric mucosal prostaglandin formation and, in parallel, inhibits mucosal thromboxane synthesis" 09/01/1983 - "Effects of carbenoxolone on gastric release of prostaglandin (PG)E2 in patients with peptic ulcer disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cimetidine (Biomet)
2.	Bismuth
3.	cicloxolone
4.	Antacids
5.	Heptanol (1 Heptanol)
6.	Diazepam (Valium)
7.	Cholinergic Antagonists (Anticholinergics)
8.	Lipid Peroxides
9.	Aspirin (Acetylsalicylic Acid)
10.	Anticonvulsants (Antiepileptic Drugs)

Related Therapies and Procedures

1.	Bed Rest (Bedrest)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Chemoprevention
5.	Kidney Transplantation

Best Treatments:
Research Summary Report
on Duodenal Ulcer

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 553 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>